Since CAR T cell persistence in tumor tissue can significantly contribute to an enhanced anti-tumor response, we investigated tumor infiltration by CD19-specific T cells after adoptive cell therapy using CAR/CCR, CAR (2nd Gen), CAR (1st Gen), or untransduced T cells in Raji Burkitt lymphoma-bearing mice. This evidence concerns the gene CD19 and Burkitt lymphoma.